Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
9-N-Phenylmethylamino-Tacrine is a synthetic small molecule belonging to the acridine class of compounds. It is structurally related to tacrine and functions as a cholinesterase inhibitor. This compound has been investigated for its potential in treating neurodegenerative diseases such as Alzheimer's disease by inhibiting acetylcholinesterase and thereby increasing acetylcholine levels in the brain[1][2][4]. Its mechanism of action mirrors that of tacrine but with structural modifications intended to improve efficacy or reduce toxicity. As of now it remains an experimental compound without clinical approval.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 9-N-phenylmethylamino-tacrine.